Bowling Portfolio Management LLC raised its stake in Emergent Biosolutions Inc (NYSE:EBS) by 37.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,499 shares of the biopharmaceutical company’s stock after buying an additional 5,824 shares during the period. Bowling Portfolio Management LLC owned 0.05% of Emergent Biosolutions worth $624,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Hodges Capital Management Inc. purchased a new position in shares of Emergent Biosolutions during the fourth quarter valued at about $1,084,000. New York State Common Retirement Fund raised its position in shares of Emergent Biosolutions by 48.2% in the third quarter. New York State Common Retirement Fund now owns 109,712 shares of the biopharmaceutical company’s stock valued at $3,459,000 after buying an additional 35,707 shares in the last quarter. FMR LLC raised its position in Emergent Biosolutions by 39.7% in the fourth quarter. FMR LLC now owns 288,348 shares of the biopharmaceutical company’s stock worth $9,469,000 after buying an additional 81,898 shares during the period. Russell Investments Group Ltd. bought a new position in Emergent Biosolutions during the fourth quarter worth $14,824,000. Finally, SECOR Capital Advisors LP raised its position in Emergent Biosolutions by 20.2% in the third quarter. SECOR Capital Advisors LP now owns 64,797 shares of the biopharmaceutical company’s stock worth $2,043,000 after buying an additional 10,906 shares during the period. Institutional investors and hedge funds own 89.61% of the company’s stock.
Emergent Biosolutions Inc (NYSE:EBS) traded down 4.06% during mid-day trading on Friday, hitting $29.51. The company’s stock had a trading volume of 447,158 shares. The firm’s 50-day moving average is $29.24 and its 200-day moving average is $29.97. The company has a market cap of $1.20 billion, a P/E ratio of 26.09 and a beta of 1.02. Emergent Biosolutions Inc has a 12-month low of $24.47 and a 12-month high of $44.38.
Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by $0.08. Emergent Biosolutions had a net margin of 9.12% and a return on equity of 10.42%. The firm earned $116.90 million during the quarter, compared to analyst estimates of $121.30 million. During the same period in the previous year, the company earned $0.16 earnings per share. Emergent Biosolutions’s revenue was up 13.5% on a year-over-year basis. Analysts predict that Emergent Biosolutions Inc will post $1.52 EPS for the current fiscal year.
EBS has been the subject of a number of analyst reports. Chardan Capital reaffirmed a “buy” rating and set a $47.00 price objective on shares of Emergent Biosolutions in a research report on Monday, January 30th. Zacks Investment Research raised Emergent Biosolutions from a “sell” rating to a “hold” rating in a research report on Tuesday, February 21st. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Emergent Biosolutions in a research report on Monday, January 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Emergent Biosolutions currently has an average rating of “Buy” and a consensus price target of $39.40.
In related news, EVP Adam Havey sold 11,419 shares of the company’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $28.62, for a total value of $326,811.78. Following the transaction, the executive vice president now directly owns 26,046 shares of the company’s stock, valued at approximately $745,436.52. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jerome M. Hauer sold 2,576 shares of the company’s stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $31.27, for a total value of $80,551.52. Following the completion of the transaction, the director now directly owns 17,404 shares in the company, valued at $544,223.08. The disclosure for this sale can be found here. 17.20% of the stock is owned by corporate insiders.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).